An immunotherapy drug could help some cancer patients live years longer without the disease worsening or recurring, according to a new trial. The study revealed that pembrolizumab, sold under the ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

Positive developments in the late-stage trials for Merck’s Keytruda immunotherapy lung cancer treatment led the company’s stock to spike nearly 4 percent April 9, according to Fortune. The KEYNOTE-o42 ...

BOISE, ID, UNITED STATES, November 20, 2025 /EINPresswire.com/ -- In recent years, immunotherapy checkpoint inhibitors have transformed from an emerging scientific ...

Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE:MRK) immunotherapy Keytruda, cut the risk of disease progression or death ...